Literature DB >> 27125203

How can we know if new drugs are effective in myeloproliferative neoplasm-associated myelofibrosis?

G Barosi1, R P Gale2.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 27125203     DOI： 10.1038/leu.2016.75

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  36 in total

1.  Do current response criteria in classical Ph-negative myeloproliferative neoplasms capture benefit for patients?

Authors:  G Barosi; A Tefferi; T Barbui
Journal:  Leukemia       Date:  2011-11-22       Impact factor: 11.528

2.  A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis.

Authors:  Alessandro M Vannucchi; Hagop M Kantarjian; Jean-Jacques Kiladjian; Jason Gotlib; Francisco Cervantes; Ruben A Mesa; Nicholas J Sarlis; Wei Peng; Victor Sandor; Prashanth Gopalakrishna; Abdel Hmissi; Viktoriya Stalbovskaya; Vikas Gupta; Claire Harrison; Srdan Verstovsek
Journal:  Haematologica       Date:  2015-06-11       Impact factor: 9.941

3.  JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.

Authors:  Claire Harrison; Jean-Jacques Kiladjian; Haifa Kathrin Al-Ali; Heinz Gisslinger; Roger Waltzman; Viktoriya Stalbovskaya; Mari McQuitty; Deborah S Hunter; Richard Levy; Laurent Knoops; Francisco Cervantes; Alessandro M Vannucchi; Tiziano Barbui; Giovanni Barosi
Journal:  N Engl J Med       Date:  2012-03-01       Impact factor: 91.245

4.  Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1.

Authors:  S Vincent Rajkumar; Jean-Luc Harousseau; Brian Durie; Kenneth C Anderson; Meletios Dimopoulos; Robert Kyle; Joan Blade; Paul Richardson; Robert Orlowski; David Siegel; Sundar Jagannath; Thierry Facon; Hervé Avet-Loiseau; Sagar Lonial; Antonio Palumbo; Jeffrey Zonder; Heinz Ludwig; David Vesole; Orhan Sezer; Nikhil C Munshi; Jesus San Miguel
Journal:  Blood       Date:  2011-02-03       Impact factor: 22.113

5.  Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.

Authors:  Srdan Verstovsek; Hagop Kantarjian; Ruben A Mesa; Animesh D Pardanani; Jorge Cortes-Franco; Deborah A Thomas; Zeev Estrov; Jordan S Fridman; Edward C Bradley; Susan Erickson-Viitanen; Kris Vaddi; Richard Levy; Ayalew Tefferi
Journal:  N Engl J Med       Date:  2010-09-16       Impact factor: 91.245

6.  Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia.

Authors:  Bruce D Cheson; Peter L Greenberg; John M Bennett; Bob Lowenberg; Pierre W Wijermans; Stephen D Nimer; Antonio Pinto; Miloslav Beran; Theo M de Witte; Richard M Stone; Moshe Mittelman; Guillermo F Sanz; Steven D Gore; Charles A Schiffer; Hagop Kantarjian
Journal:  Blood       Date:  2006-04-11       Impact factor: 22.113

7.  Failure-free survival in a prospective cohort of patients with chronic graft-versus-host disease.

Authors:  Jeanne Palmer; Xiaoyu Chai; Paul J Martin; Daniel Weisdorf; Yoshihiro Inamoto; Joseph Pidala; Madan Jagasia; Steven Pavletic; Corey Cutler; Georgia Vogelsang; Sally Arai; Mary E D Flowers; Stephanie J Lee
Journal:  Haematologica       Date:  2015-02-24       Impact factor: 9.941

8.  Improvement of bone marrow fibrosis with ruxolitinib: will this finding change our perception of the drug?

Authors:  Massimo Breccia; Matteo Molica; Gioia Colafigli; Giuliana Alimena
Journal:  Expert Rev Hematol       Date:  2015-04-27       Impact factor: 2.929

Review 9.  Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT).

Authors:  G Barosi; A Tefferi; C Besses; G Birgegard; F Cervantes; G Finazzi; H Gisslinger; M Griesshammer; C Harrison; R Hehlmann; S Hermouet; J-J Kiladjian; N Kröger; R Mesa; M F Mc Mullin; A Pardanani; F Passamonti; J Samuelsson; A M Vannucchi; A Reiter; R T Silver; S Verstovsek; G Tognoni; T Barbui
Journal:  Leukemia       Date:  2014-08-25       Impact factor: 11.528

Review 10.  Dose escalation methods in phase I cancer clinical trials.

Authors:  Christophe Le Tourneau; J Jack Lee; Lillian L Siu
Journal:  J Natl Cancer Inst       Date:  2009-05-12       Impact factor: 13.506
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.